Higher mTOR Expression: A Marker of Poor Outcome in Patients with de Novo AML.

UNLABELLED

Acute myeloid leukemia (AML) displays significant clinical diversity mainly due to the variation in the underlying molecular defects, which is now recognized as the main driver for leukemogenesis. mTOR deregulation is thought to promote the proliferation and survival of leukemic blasts. This work aimed to study gene expression as a prognostic marker and a potential therapeutic target in AML. Quantitative real-time PCR evaluated expression in 45 new AML cases in relation to disease characteristics and outcome. mTOR was overexpressed in AML patients and higher levels were seen in the group that was not in complete remission (CR), at the end of induction, compared to those who achieved remission (17.03 ± 16.44 vs 3.91 ± 2.55 respectively,  < 0.001). In addition, expression inversely correlated with survival ( < 0.001). Patients with mTOR expression > 5.2 had a median overall survival of 10 months as opposed to 23 months in those with an expression of ≤ 5.2,  < 0.001. mTOR was an independent risk factor for failure of response in our patient group ( 0.007 and OR 1.54). mTOR has prognostic implications as it predicted the response and survival in our patients.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s12288-022-01569-3.